by myNEO Tx Admin | Jan 28, 2025 | Careers
Are you passionate about actively helping to innovate and transform immunotherapies, alongside accomplished biotech experts? Are you looking for an ambitious position to expand your knowledge? Who are we? myNEO is a Belgian bio-tech company in Ghent,...The process starts with the collection of both patient blood and a tumor biopsy.
Whole-Genome Sequencing data from matched tumor and normal DNA is required for each patient.
Following alignment of these reads to the genome, somatic gene alterations in the tumor genome are detected using a collection of algorithms called 'neoX'.
Next, these somatic gene alterations are translated in-silico to obtain the tumor-specific peptides
In a last step, the peptides are prioritized using an immunogenicity predictor (neoIM) and two presentation predictors (neoMS and MHCrank).